Uterine Fibroids Drug Market Size, Business Revenue Forecast, Leading Competitor

Posted by kelvindbmr on April 19th, 2021

Global uterine fibroids drug market is expected to grow at a substantial CAGR in the forecast period of 2020-2026. Uterine fibroids are also known as leiomyoma or myomas, can be characterized by the formation of abnormal non-cancerous tissue growth inside the wall of the uterus.

Competitive Analysis: Global Uterine Fibroids Drug Market

Global uterine fibroids drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uterine fibroids drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Download PDF Sample report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-fibroids-drug-market

A woman may develop one or many fibroids in uterus and these can vary in sizes depending upon the condition and level. Uterine fibroids symptoms include heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping and enlargement of the abdomen.

Segmentation: Global Uterine Fibroids Drug Market

•          By Types (Subserosal Fibroids, Submucosal Fibroids, Intramural Fibroids and Pedunculated Fibroids)
•          By Mechanism of Action (GnRH Agonists, Steroids, Contraceptives, NSAIDs and Vitamins)
•          By Drugs Type (Progesterone, Levonorgestrel, Mefenamic, Raloxifene and Others)
•          By Diagnosis (Ultrasound, Lab Tests and Imaging Tests)
•          By Treatment (Medication, Dietary Supplements and Surgery)
•          By Route of Administration (Oral, Intravenous and Others)
•          By End-Users (Hospitals, Homecare, Specialty Clinics and Others)
•          By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Key Market Players: Global Uterine Fibroids Drug Market

The key market players in the global uterine fibroids drug market are GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc, Medtronic, Endo Pharmaceuticals Inc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Hologic, Inc, Smith & Nephew, Merck & Co., Inc, ALLERGAN, Bayer AG, Koninklijke Philips N.V, IceCure Medical Ltd and others.

Market Drivers

•          Increasing prevalence of uterine fibroids is driving the market growth
•          Rising female population across the globe is driving the market growth.Growing screening across the world can also acts as a market driver
•          Rising awareness amongst people about the uterine fibroids and its treatment is also boosting the market growth

Market Restraints

•          Side effects of treatment such as bleeding and infection during surgery can hamper the market growth
•          Low healthcare expenditure in developing regions also restricts the market growth
•          High cost-containment measures undertaken by governments along with the ongoing healthcare reforms.
•          Limited treatment options for uterine fibroids are restricting the market growth.